Breast

IRB #H-39510/ DFCI 17-101 (PACE): Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

CIRB #H-37507/ CTSU #A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

CIRB #H-40381/ CTSU #EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients who Achieve a Pathologic Complete Response (Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)

IRB #H-33188/ BMC #DOSI: Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI)

IRB #H-37386/ CTSU #EA1151 (TMIST): Tomosynthesis Mammographic Imaging Screening Trial